Clinical Trials List
2025-05-01 - 2030-12-01
Phase III
Recruiting5
ICD-10C34.90
Malignant neoplasm of unspecified part of unspecified bronchus or lung
ICD-10C34.91
Malignant neoplasm of unspecified part of right bronchus or lung
ICD-10C34.92
Malignant neoplasm of unspecified part of left bronchus or lung
ICD-10C7A.090
Malignant carcinoid tumor of the bronchus and lung
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9162.9
Malignant neoplasm of bronchus and lung, unspecified
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/10
Investigators and Locations
Co-Principal Investigator
- 蔡子修 無
- 許嘉林 無
- James Chih-Hsin Yang 無
- 吳尚俊 無
- 廖斌志 無
- CHAO-CHI HO CHAO-CHI HO 無
- 廖唯昱 無
- JIN-YUAN SHIH 無
- Jih-Hsiang Lee 無
- 吳宗哲 無
- 楊景堯 無
- YEN-TING LIN 無
- 徐偉勛 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 李玫萱 無
- 莊政皓 無
- 郭家佑 無
- Ying-Ming Tsai Tsai 無
- Inn-Wen Chong 無
- Jen-Yu Hung 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chih-Liang Wang 無
- 林定佑 無
- Chih-Hung Chen 無
- Chan-Keng Yang 無
- Shih-Hong Li 無
- Ping-Chih Hsu 無
- Cheng-Ta Yang 無
- Jia-Shiuan Ju 無
- 邱立忠 無
- 黃振洋 無
- 枋岳甫 無
- Chih-Hsi Kuo 無
- Chien-Ying Liu 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
DOCETAXEL
Dosage Form
27C
Dosage
160mg/8ml
Endpoints
Inclution Criteria
At least 18 years old and has provided informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy.
Measurable disease per RECIST v1.1.
Adequate organ function (bone marrow, liver, kidney, coagulation).
One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy.
Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).
Able to take oral medications.
Exclusion Criteria
Prior therapy with direct RAS-targeted therapy or docetaxel.
Untreated central nervous system (CNS) metastases.
Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function).
Ongoing anticancer therapy.
Pregnant or breastfeeding.
The Estimated Number of Participants
-
Taiwan
13 participants
-
Global
420 participants
